| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/24/2003 | WO2003032973A2 Composition comprising paracetamol and a bitterness masking component |
| 04/24/2003 | WO2003032967A1 Method of stabilizing reduced coenzyme q10 |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032960A1 Percutaneous absorption preparations |
| 04/24/2003 | WO2003032956A1 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline |
| 04/24/2003 | WO2003032955A1 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | WO2003032952A1 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease |
| 04/24/2003 | WO2003032950A1 Pharmaceutical formulation comprising (r) -bicalutamide |
| 04/24/2003 | WO2003032949A1 Novel cyclosporin analog microemulsion preconcentrates |
| 04/24/2003 | WO2003032948A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 04/24/2003 | WO2003032947A2 A method for preparing liposome formulations with a predefined release profile |
| 04/24/2003 | WO2003032944A1 Anti-microbial composition comprising a metal ion chelating agent |
| 04/24/2003 | WO2003032942A1 Cosmetic and/or pharmaceutical preparations |
| 04/24/2003 | WO2003032931A1 Cosmetic and/or pharmaceutical preparations |
| 04/24/2003 | WO2003032922A2 Stabilized azithromycin compositions |
| 04/24/2003 | WO2003032913A2 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/24/2003 | WO2003032912A2 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | WO2003032907A2 High-concentration protein formulations and method of manufacture |
| 04/24/2003 | WO2003032906A2 Delivery of poorly soluble drugs |
| 04/24/2003 | WO2003032904A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | WO2003032899A2 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | WO2003032814A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 04/24/2003 | WO2003032728A2 Methods for preventing or reversing asthma and compositions useful therefor |
| 04/24/2003 | WO2003032727A1 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| 04/24/2003 | WO2003007782A3 Biodegradable injectable implants and related methods of manufacture and use |
| 04/24/2003 | WO2002102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT |
| 04/24/2003 | WO2002100437A3 Ophthalmic compositions comprising hyaluronic acid |
| 04/24/2003 | WO2002097072A3 Influenza vaccine composition |
| 04/24/2003 | WO2002087614A3 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| 04/24/2003 | WO2002085292A3 Improved method for treating aberrant fibrotic tisue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof |
| 04/24/2003 | WO2002070438A3 Compositions for delivering bisphosphonates |
| 04/24/2003 | WO2002066490A3 Cationic sterol derivatives, ph-sensitive liposomes comprising cationic sterol derivatives and method for loading liposomes with active substances |
| 04/24/2003 | WO2002066018A3 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 04/24/2003 | WO2002045707A3 Polynucleotide intercalator interceptors and inhibitors |
| 04/24/2003 | WO2002038171A3 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 04/24/2003 | WO2002031498A3 Protecting therapeutic compositions from host-mediated inactivation |
| 04/24/2003 | WO2002024180A3 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
| 04/24/2003 | WO2002012369A9 Lactic acid polymer and process for producing the same |
| 04/24/2003 | WO2001080900A3 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| 04/24/2003 | US20030078532 Composite dressings for the treatment of wounds |
| 04/24/2003 | US20030078517 In vivo delivery methods and compositions |
| 04/24/2003 | US20030078376 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 04/24/2003 | US20030078371 Glycopeptide for use in the prevention and treatment of bacterial infections |
| 04/24/2003 | US20030078365 Novel polymers for delivering nitric oxide in vivo |
| 04/24/2003 | US20030078302 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration |
| 04/24/2003 | US20030078266 Powder of 30-90% a water-soluble cycloxygenase inhibitor, 5-60% of a buffer and 0-10% of other excipients |
| 04/24/2003 | US20030078241 Treating effects of excessive reactive oxygen species |
| 04/24/2003 | US20030078238 Stabilization method of nano-sized emulsion using tocopheryl derivatives and external application for skin containing the same |
| 04/24/2003 | US20030078215 Wherein biological activity of bioactive agent/complexing agent complex is higher than activity of uncomplexed bioactive agent |
| 04/24/2003 | US20030078194 Comprises liposome core containing drugs (insulin) encapsulated within fatty acid membrane |
| 04/24/2003 | US20030078189 Medicinal compositions for oral use |
| 04/24/2003 | US20030077829 Lipid-based formulations |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077818 Fusion protein for use in the treatment of tumors and cancer disorders |
| 04/24/2003 | US20030077813 Structure of adenovirus bound to cellular receptor car |
| 04/24/2003 | US20030077763 Polymer grafting by polysaccharide synthases |
| 04/24/2003 | US20030077753 Diglycosylated erythropoietin |
| 04/24/2003 | US20030077682 Arginine free composition for use in treatment of thrombsis |
| 04/24/2003 | US20030077614 Nucleic acids for inhibiting hairless protein expression and methods of use thereof |
| 04/24/2003 | US20030077568 Screening drugs; obtain cell with preferential phenotypic profile, incubate with drug, monitor effect on cells |
| 04/24/2003 | US20030077377 Edible powder material having excellent shelf stability |
| 04/24/2003 | US20030077334 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanism for normal and transformed cells |
| 04/24/2003 | US20030077332 Wound healing agents; viricides |
| 04/24/2003 | US20030077330 Respiratory system disorders; remove carbon dioxide from blood |
| 04/24/2003 | US20030077329 Composition of and method for preparing stable particles in a frozen aqueous matrix |
| 04/24/2003 | US20030077327 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | US20030077326 Mixture containing water insoluble polymer, plasticizer and drug; film forming |
| 04/24/2003 | US20030077325 Mixture of drug and hydrophilic polymer; water solubility |
| 04/24/2003 | US20030077322 Solid dispersion system of pranlukast with improved dissolution and method for preparing the same |
| 04/24/2003 | US20030077317 Drug delivery; adhesion to mucous membranes; biopolymer |
| 04/24/2003 | US20030077313 Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| 04/24/2003 | US20030077308 Topical compositions for veterinary uses |
| 04/24/2003 | US20030077307 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 04/24/2003 | US20030077306 Emulsions as solid dosage forms for oral administration |
| 04/24/2003 | US20030077305 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells |
| 04/24/2003 | US20030077304 Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis |
| 04/24/2003 | US20030077303 Consists of naproxen, a butyl spacer and a nitrogen oxide (NO)-releasing nitrate group, linked together into a single molecule; useful as antiinflammatory agent and an analgesic |
| 04/24/2003 | US20030077302 An ophthalmic formulation for glaucoma treatment in the form of a suspension gel containing the free acid of diclofenamide, preservatives, gel forming agent and agents to adjust the pH |
| 04/24/2003 | US20030077301 Topically administering to a localized region affected by the inflammatory dermatosis on a patient skin a formulation containing a active agent,and a permeation enhancing base to enhance the flux of active agent through skin without damage |
| 04/24/2003 | US20030077295 Dendritic-platinate drug delivery system |
| 04/24/2003 | US20030077287 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 04/24/2003 | US20030077285 Methods of diagnosis and treatment by binding p75/airm1 |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077272 Proteinaceous gels having visualization agents and methods of use thereof |
| 04/24/2003 | US20030077268 Recombinant bacterial cells for delivery of PNP to tumor cells |
| 04/24/2003 | US20030077260 Hybrid matrix implants and explants |
| 04/24/2003 | US20030077258 Comprising one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft |
| 04/24/2003 | US20030077253 Implantable or insertable therapeutic agent delivery device |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077245 A polyalkylene oxide-ethylene oxide block copolymer as antigrowth agents |
| 04/24/2003 | US20030077244 A biocompatible crosslinking polymer comprising acrylamide and methylene bis-acrylamide; medical procedure involves injection of polyacrylamide gel under the mucous membrane |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | US20030077242 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 04/24/2003 | US20030077240 Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions |
| 04/24/2003 | US20030077239 Composition for the antidandruff treatment of the hair and scalp based on an antidandruff active principle and on a hydroxy acid |
| 04/24/2003 | US20030077230 Container equipped with a metering valve and containing a pressurized formulation of beta-agonist drug, a fluoroalkane propellant and > 5% of a solvent |
| 04/24/2003 | CA2781766A1 Method of stabilizing reduced coenzyme q10 |